Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | BBOX1 | O75936 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | APEX1 | P27695 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8448319 | 0.98 | ACHE (0.50) | ACHEBBOX1MEN1NFKB1KMT2A | |
| SCHEMBL15397899 | 0.94 | ACHE (0.45) | ACHEBBOX1MEN1NFKB1KMT2A | |
| SCHEMBL612764 | 0.92 | APOBEC3A (0.44) | ACHEMEN1NFKB1KMT2AAPEX1 | |
| SCHEMBL1974755 | 0.86 | ACHE (0.39) | ACHEBBOX1LMNASMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL6550830 | 0.84 | ACHE (0.38) | ACHEBBOX1LMNASMN1; SMN2TSHR | |
| Methacrylic Acid SCHEMBL159154 | 0.83 | ACHE (0.48) | ACHEBBOX1SMN1; SMN2ENPP2ADRA2A | |
| SCHEMBL1424686 | 0.82 | ACHE (0.38) | ACHEBBOX1 | |
| SCHEMBL3210702 | 0.82 | BBOX1 (0.66) | ACHEBBOX1KMT2A | |
| Sulfuric Acid SCHEMBL16196071 | 0.79 | ACHE (0.34) | ACHEBBOX1ENPP2ADRA2AADRA1A | |
| Hydrochloric Acid SCHEMBL2936558 | 0.78 | ACHE (0.52) | ACHEBBOX1MEN1NFKB1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658741-A1 | LAUNDRY CARE COMPOSITION | Givaudan SA (CH) | 2025-12-10 | — | — | EP | claimed |
| WO-2024160709-A1 | LAUNDRY CARE COMPOSITION | GIVAUDAN SA (CH) | 2024-08-08 | — | — | WO | claimed |
| EP-3246048-B1 | BI-FUNCTIONAL CO-POLYMER USE FOR OPHTHALMIC APPLICATIONS | CALM WATER THERAPEUTICS LLC (US) | 2024-04-03 | — | — | EP | claimed |
| US-20230090391-A1 | OMECAMTIV MECARBIL TABLET | AMGEN INC. | 2023-03-23 | — | — | US | claimed |
| EP-4103159-A1 | OMECAMTIV MECARBIL TABLET | Amgen Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| WO-2022221942-A1 | PREVENTION OF DRUG DIVERSION | BETTERLIFE PHARMA INC. (CA) | 2022-10-27 | — | — | WO | claimed |
| EP-3613414-A1 | PELLETS WITH MULTILAYER STRUCTURE FOR DELAYED RELEASE OF THE DRUG IN THE DISTAL COLON | Dr. Falk Pharma Gmbh (DE) | 2020-02-26 | — | — | EP | claimed |
| US-10568946-B2 | Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes | OXTHERA INTELLECTUAL PROPERTY AB (SE) | 2020-02-25 | — | — | US | claimed |
| US-20180169196-A1 | PURIFICATION AND ISOLATION OF RECOMBINANT OXALATE DEGRADING ENZYMES AND SPRAY-DRIED PARTICLES CONTAINING OXALATE DEGRADING ENZYMES | OXTHERA INTELLECTUAL PROPERTY AB (SE) | 2018-06-21 | — | — | US | claimed |
| US-9833499-B2 | Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes | OXTHERA INTELLECTUAL PROPERTY AB (SE) | 2017-12-05 | — | — | US | claimed |
| EP-1502587-B1 | Sustained release formulation for Venlafaxine hydrochloride | PHARMATHEN SA (GR) | 2006-08-23 | — | — | EP | claimed |
| EP-1322276-B1 | TOOTH COATING COMPOSITION | PATACCA THOMAS R (US) | 2006-03-29 | — | — | EP | claimed |
| EP-0975314-B1 | CAPILLARY COSMETIC COMPOSITIONS BASED ON CATIONIC POLYMERS AND NON-IONIC ASSOCIATIVE POLYMERS | OREAL (FR) | 2005-08-24 | — | — | EP | claimed |
| US-20040102554-A1 | Tooth coating composition | NUDENT, L.L.C. | 2004-05-27 | — | — | US | claimed |
| EP-1267932-B1 | ANTI-INFECTIVE ACTIVE SUBSTANCE COMBINATIONS AND THE USE THEREOF FOR THE TOPICAL TREATMENT OF FUNGUS DISEASES OF TOE AND FINGER NAILS | AVENTIS PHARMA GMBH (DE) | 2004-02-18 | — | — | EP | claimed |
| EP-0900563-B1 | Production of pharmaceutical formulations containing aescin for treatment of edema and venous disorders | KLINGE CO CHEM PHARM FAB (DE) | 2004-02-11 | — | — | EP | claimed |
| EP-0855903-B1 | COSMETIC COMPOSITION FOR THE TREATMENT OF KERATINOUS MATERIALS COMPRISING AT LEAST A GRAFTED SILICONE POLYMER AND AT LEAST AN AQUEOUS DISPERSION OF INSOLUBLE PARTICLES OF NON IONIC OR CATIONIC POLYMER | OREAL (FR) | 2002-08-14 | — | — | EP | claimed |
| US-6022554-A | LONG TERM SUSTAINED-RELEASE IMPLANT COMPRISING A DRUG AND FILM COAT OF A WATER INSOLUBLE POLYMER AND POLYETHYLENE GLYCOL AS A WATER SOLUBLE PORE FORMING AGENT TO REGULATE RELEASE OF THE DRUG FOR A DURATION OF GREATER THAN 100 DAYS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-02-08 | — | — | US | claimed |
| WO-1999030685-A1 | POLYMERIC MICROPOROUS FILM COATED SUBCUTANEOUS IMPLANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-06-24 | — | — | WO | claimed |
| US-3965032-A | POLYELECTROLYTE | THE DOW CHEMICAL COMPANY (US) | 1976-06-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230090391-A1 | OMECAMTIV MECARBIL TABLET | SLC5A1, SLC16A1, SLC5A2 | ACHE 1435/4885BBOX1 4698/4885MEN1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.